Evaluation of the pharmacokinetics and food intake effect of generic sofosbuvir in healthy Chinese subjects

被引:3
|
作者
Li, Xin [1 ]
Liu, Yujie [2 ]
Xu, Bing [1 ]
Liu, Lihua [1 ]
Li, Yuan [1 ]
Zhang, Ping [3 ]
机构
[1] Third Hosp Changsha, Dept Pharm, Changsha, Hunan, Peoples R China
[2] Nanjing Chia Tai Tianqing Pharmaceut Co Ltd, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Clin Tech Labs Inc, Nanjing, Jiangsu, Peoples R China
关键词
generic sofosbuvir; pharmacokinetics; food effect; hepatitis C; healthy Chinese; HEPATITIS-C VIRUS; POLYMERASE INHIBITOR; INFECTION;
D O I
10.5414/CP203649
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Sofosbuvir is an NS5B nucleotide inhibitor that was approved for hepatitis C treatment. Generic sofosbuvir has been produced to improve the affordability. The present study investigated the pharmacokinetics (PK) and safety of generic sofosbuvir as well as the effect of food intake on its PK parameters in healthy Chinese subjects. Materials and methods: This open-label, randomized, multiple-dose, dose-escalating, and food effect trial enrolled 12 healthy Chinese subjects. The subjects received a single oral dose of 400 mg of generic sofosbuvir in fasted state or after a high-fat meal. or 800 mg in fasted state, in a three-way crossover design, and then all subjects were administered with 400 mg daily for 8 days. The PK parameters for sofosbuvir and its metabolites were determined, and the safety was monitored. Results: Sofosbuvir was absorbed rapidly into plasma. with a half-life of 0.46 - 0.48 hours. Plasma exposure to sofosbuvir and its metabolite GS-566500 was increased in an approximately proportional manner to the increased dose. Repeated dosing did not result in drug accumulation in the blood. Sofosbuvir was mainly excreted as the metabolite GS-331007 in the urine. Drug administration after a high-fat meal increased the plasma sofosbuvir exposure by 1.29-fold, without substantially altering the absorption rate. No serious adverse events were observed, and all subjects tolerated the doses well. Conclusion: This generic sofosbuvir was well absorbed, the plasma concentration was increased with an increased dose. and it was safe in healthy subjects. A high-fat meal appeared to promote the bioavailability of sofosbuvir and the metabolite GS-566500. What is known about this subject - Pharmacokinetics of single and multiple dose (400 mg) brand-name sofosbuvir in healthy Chinese subjects under fasting conditions have been studied. What this study adds - This study evaluated the pharmacokinetic profile of generic sofosbuvir in healthy Chinese subjects. - This generic sofosbuvir was well absorbed, and the plasma concentration was increased with an increased dose. A high-fat meal appeared to promote the bioavailability of this drug and the metabolite GS-566500. - Sofosbuvir at doses up to 800 mg was well tolerated.
引用
收藏
页码:230 / 241
页数:12
相关论文
共 50 条
  • [1] Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects
    Sachar, Madhav
    Park, Cheol Hee
    Pesco-Koplowitz, Luana
    Koplowitz, Barry
    McGinn, Arlo
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 (01) : 171 - 181
  • [2] Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects
    Li, Cuiyun
    Li, Xiaojiao
    Zhu, Xiaoxue
    Zhang, Hong
    Shen, Gong
    Kersey, Kathryn
    Ding, Yanhua
    CLINICAL THERAPEUTICS, 2020, 42 (03) : 448 - 457
  • [3] Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects
    Dien, TK
    deVries, PJ
    Khanh, NX
    Koopmans, R
    Binh, LN
    Duc, DD
    Kager, PA
    vanBoxtel, CJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1069 - 1072
  • [4] Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake
    Wen, Yu-Guan
    Shang, De-Wei
    Xie, He-Zhi
    Wang, Xi-Pei
    Ni, Xiao-Jia
    Zhang, Ming
    Lu, Wei
    Qiu, Chang
    Liu, Xia
    Li, Fang-Fang
    Li, Xuan
    Luo, Fu-Tian
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2013, 28 (02) : 134 - 141
  • [5] Effects of food on the pharmacokinetics of ensartinib in healthy Chinese subjects
    Shao, Rong
    Chen, Wenjun
    Ruan, Zourong
    Yang, Dandan
    Chen, Wanlin
    Li, Hua
    Lou, Honggang
    Chen, Jingliang
    Jiang, Bo
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (03) : 360 - 369
  • [6] Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects
    Meng, Xianmin
    Lin, Xiaoyan
    Jiang, Rongrong
    Lu, Yan
    Zeng, Liyan
    Cao, Ming
    Zhang, Jianliang
    CLINICAL DRUG INVESTIGATION, 2022, 42 (11) : 1009 - 1016
  • [7] Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects
    Xianmin Meng
    Xiaoyan Lin
    Rongrong Jiang
    Yan Lu
    Liyan Zeng
    Ming Cao
    Jianliang Zhang
    Clinical Drug Investigation, 2022, 42 : 1009 - 1016
  • [8] Pharmacokinetics and Bioequivalence of a Generic and a Branded Pazopanib Tablet in Healthy Chinese Subjects
    Liu, Lihua
    Li, Xin
    Liu, Yujie
    Li, Yuan
    Deng, Yang
    Zhang, Ping
    Tu, Shengqing
    Wang, Keli
    Xu, Bing
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1110 - 1115
  • [9] Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects
    Dai, Jun
    Cheng, Yang
    Zhou, Yannan
    Wang, Yanli
    Liu, Zhengzhi
    Ren, Qing
    Su, Zhengjie
    Deng, Qiaohuan
    Yang, Haimiao
    Cui, Yingzi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [10] Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese Subjects
    Li, Xin
    Li, Yuan
    Xu, Bing
    Zhang, Ping
    Wang, Yangyang
    Wang, Zhenyu
    Hou, Shuguang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (04): : 516 - 522